Related Experiment Video
Updated: May 6, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Statin therapy for atherogenic hypertriglyceridemia]
1Division of Cardiology, Department of Medicine, Showa University School of Medicine.
Insights
Statins effectively lower LDL-cholesterol, reducing heart disease and stroke risk. Stronger statins like rosuvastatin offer greater reductions in triglycerides and small dense LDL particles.
Area of Science:
- Cardiovascular Pharmacology
- Lipid Metabolism
- Pharmacotherapy
Context:
- Statins are primary agents for lowering low-density lipoprotein (LDL) cholesterol.
- Elevated LDL and triglycerides are key risk factors for coronary heart disease (CHD) and ischemic stroke.
- Accumulation of remnant lipoproteins contributes to atherogenic small dense LDL formation.
Purpose:
- To highlight the efficacy of statins in managing dyslipidemia.
- To differentiate the lipid-lowering effects of various statin potencies.
- To emphasize the role of statins in reducing cardiovascular morbidity and mortality.
Summary:
- Statins significantly reduce morbidity and mortality associated with CHD and ischemic stroke by lowering LDL-cholesterol.
- Strong statins (rosuvastatin, atorvastatin, pitavastatin) demonstrate superior efficacy in reducing triglycerides and small dense LDL compared to other statins.
- Statins are first-line treatments for hypertriglyceridemia with elevated LDL- and/or non-HDL cholesterol, with aggressive lowering needed for high-risk CHD patients.
Impact:
- Provides evidence for selecting potent statins in high-risk cardiovascular patients.
- Informs clinical practice regarding lipid management strategies.
- Contributes to understanding the mechanisms of statin action on atherogenic lipoproteins.
Abstract:
LDL-cholesterol lowering by statins substantially reduces morbidity and mortality of coronary heart disease (CHD) and ischemic stroke. Statins are the most potent agents for lowering circulating LDL particles. Accumulation of triglyceride-rich remnant lipoproteins in both fasting and postprandial state is strongly associated with the formation of highly atherogenic small dense LDL. Although dose-dependent reductions in levels of atherogenic lipids are observed with all statin, strong statins such as rosuvastatin, atorvastatin, and pitavastatin, can reduce the triglyceride and small dense LDL greater than other statins. Statin is one of the first-line drugs for management of hypertriglyceridemia with elevated LDL-cholesterol and/or non HDL-cholesterol. Aggressive LDL-cholesterol lowering may be required for the management of high-risk CHD patients with both high LDL-cholesterol and triglyceride.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Cholesterol: Significance and Regulation
Considering cholesterol and...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Angina IV: Management
